ODS Acting Director
This article was originally published in The Tan Sheet
Ralph Lillie has been named acting director of the Office of Drug Safety, the Center for Drug Evaluation & Research announced Jan. 23; he will remain in place as the center searches for a permanent director, according to CDER Acting Director Steve Galson. Lillie has led emergency preparedness efforts in the Office of Executive Operations, and was deputy director of the Office of Postmarketing Drug Risk Assessment from 1997 to 1999...
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.